182 results on '"Moreaux, Jerome"'
Search Results
2. PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma
3. KDM6A controls immunogenicity in MM
4. Development of a Robust BH3 Profiling Toolkit for Precision Medicine in Hematologic Malignancies
5. Targeting Iron Homeostasis As a Therapeutic Strategy in Multiple Myeloma
6. EZH2 Targeting Induces CD38 Upregulation and Response to Anti-CD38 Antibodies in Multiple Myeloma
7. Ironomycin Induces Mantle Cell Lymphoma Cell Death By Targeting Iron Metabolism Addiction
8. Clinical and prognostic role of annexin A2 in multiple myeloma
9. Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration
10. Exploiting Transcription-Replication Conflicts As a Novel Therapeutic Intervention in Multiple Myeloma
11. Preliminary Study of Ruxolitinib and Venetoclax for Treatment of Patients with T-Cell Prolymphocytic Leukemia Refractory to, or Ineligible for Alemtuzumab
12. Genomic Characterization of in Vitro Acquired-Resistance to Proteasome Inhibitors
13. Induction of angiogenesis by normal and malignant plasma cells
14. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor
15. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma
16. Early Progressions of Undetermined Significance (EPUS) in the Month Following CAR-T Cells for B-Cell NHL Is Mainly Related to Pseudoprogression
17. Epigenetic Modifiers MMSET and EZH2 Physically Interact and Cooperate to Support Multiple Myeloma Pathophysiology
18. Integrative Multi-Omics Analysis of Tumor-Immune Microenvironment in Multiple Myeloma: Novel Insights and Therapeutic Implications
19. Lipid-Mediated Modulation of DNA Damage Signaling As a Prognostic and Therapeutic Strategy Against Multiple Myeloma
20. Characterization of a New Metabolic Score Correlated with CD38 Cell-Surface Expression and Response to Daratumumab Treatment in Multiple Myeloma
21. Translation Inhibition through eIF4A1 Targeting in Multiple Myeloma Is a Promising Therapeutic Strategy
22. Integrative Single-Cell RNA-Seq and Single-Cell ATAC-Seq Analysis of Human Plasma Cell Differentiation
23. The origin of preplasmablastic cells
24. Robust Discovery of Candidate DNA Methylation Cancer Drivers
25. Targeting DNA Repair to Overcome Drug Resistance in Hodgkin Lymphoma
26. Comprehensive Characterization of the Epigenetic Landscape in Multiple Myeloma
27. DNA Repair Expression Profiling to Identify High-Risk Cytogenetically Normal Acute Myeloid Leukemia and Define New Therapeutic Targets
28. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature
29. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone
30. RNA-Sequencing Based Assessment of Targets, Risk and Long Term Survival for Personalized Treatment of Multiple Myeloma
31. Prediction of Malingant Plasma Cell Biology Related Survival in AL-Amyloidosis
32. Ironomycin Induces Diffuse Large B-Cell Lymphoma Cell Death By Targeting Iron Metabolism Addiction
33. Targeting EZH2 in Multiple Myeloma Could be Promising for a Subgroup of MM Patients in Combination with IMiDs
34. RAS Association Domain Family Member 4 (RASSF4): A New Potent Tumor Suppressor in Multiple Myeloma
35. Identification of a Gene Signature Associated to Treatment Response to Palbociclib in Multiple Myeloma
36. Patterns of Microrna in Plasma Cells: From Normal Differentiation to Multiple Myeloma
37. A Small Molecule That Selectively Targets BLM Helicase Has a Therapeutic Interest in Multiple Myeloma
38. SET8 Is a Potential Therapeutic Target in MM
39. On the Redox Profile of B- Cell Terminal Differentiation and Multiple Myeloma: New Insights and Therapeutic Opportunities
40. Inhibition of SUV39H Methyltransferase As a Potent Therapeutic Target in Multiple Myeloma
41. Combined Inhibition of Chk1 and Wee1 As a New Therapeutic Strategy for High-Risk Multiple Myeloma Patients
42. Kinome Expression Profiling in Multiple Myeloma Identifies New Therapeutic Targets
43. Targeting DNA Repair Mechanisms to Overcome Drug Resistance in Diffuse Large B Cell Lymphoma
44. The in vivo Transcriptional Response Towards Epigenetic Modulating Agents in Multiple Myeloma
45. Role Of RECQ1 Helicase In Multiple Myeloma Biology and Drug Resistance
46. Malignant Plasma Cells Responsible for Multiple Myeloma Relapse Are Detectable and Survive Nine Days After High Dose Melphalan: Highlight of An Optimal Therapeutic Window ?
47. Myeloma Cell Self-Renewal Depends on JAG2 Expression and Is Mediated by IGF1 or SCF Loop
48. Inhibition of HIF1A Signaling by a Novel Class of Sulfonanilides for Targeted Treatment of Multiple Myeloma.
49. A Clinically Usable Gene Expression Report for Risk Assessment and Identification of Possible Therapeutic Targets in Multiple Myeloma.
50. Osteoclast Gene Expression Profiling in Multiple Myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.